Managing residual risk in patients receiving statin therapy
Author: Ian R Hamilton-Craig
Published online: 3 January 2011
In reply: In the interests of scientific exactitude, I am indebted to Marilyn Mann for corrections regarding the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. However, as the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial did not include the control group ezetimibe versus placebo, the effects of ezetimibe on carotid intima media thickness remain somewhat speculative.1
Competing interests
References
- Stein E. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem 2008; 54: 940-942. 0_JJJHADGB
Distribution of Cardiovascular Disease Risk Based on the Updated 2023 Guideline-Recommended Australian Cardiovascular Disease Risk Algorithm and Comparison With the 2012 Algorithm: An Observational Study
Nina Lazarevic, Meghana Bhat, Grace Joshy, Danielle C. Butler, Mark Woodward, Anushka Patel, Rod T. Jackson, Garry Jennings, Rosemary Wyber, Ellie Paige, Emily Banks
They Brought the Hospital to Me
Hugh N. Burrill
Temporal Trends in Preterm Birth Associated With Hypertensive Disorders of Pregnancy in Victoria, Australia: A Population-Based Interrupted Time-Series Study
Melvin Marzan, Heng Jiang, Daniel Lorber Rolnik, Joanne M. Said, Lisa Hui
Estimating Eligibility for GLP-1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross-Sectional Analysis of National Health Survey Data
Jasmin Castrillon, Chris Schilling, Sharmala Thuraisingam, Michael W. Hii, Priya Sumithran, Peter F. Choong, Michelle M. Dowsey, Cade Shadbolt
Seven Vessel Spontaneous Coronary Artery Dissection and Concurrent Transient Global Amnesia After an Emotional Trigger
Michael J. Stewart, Tom R. Sutherland